Volume Alert - GILD 105.07 Gilead Sciences $GILD Hit a high

New Post Public Reply Private Reply Replies (0) Message Board

Nov 13, 2014 at 11:02 AM

Volume Alert - GILD 105.07 Gilead Sciences $GILD Hit a high today of 107.05 Closing the day 10:30 at 105.07 -1.83 -1.71% With a day low of 104.42 and a total volume of 6,541,977.

GILD Recent Posts: http://investorshangout.com/Gilead-Sciences-Inc-GILD-54232/

GILD Gilead Sciences Recent Headline News

Why Gilead Sciences (GILD) Isn't Done Growing Earnings Yet - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - 2 hrs 18 mins ago
Gilead Sciences which is in the Biotechnology space, saw EPS growth of nearly 11% last year, and is looking great for this year too.
GILD: 105.07 (-1.83)

Gilead prices USD4bn senior unsecured notes in three tranches
M2 - Thu Nov 13, 6:01AM CST
Biopharmaceutical company Gilead Sciences (NasdaqGS:GILD) said on Wednesday that it has priced its USD4bn senior unsecured notes in a public offering.
GILD: 105.07 (-1.83)

Final Glance: Biotechnology companies
AP - Wed Nov 12, 5:02PM CST
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
GILD: 105.09 (-1.81), AMGN: 162.01 (+0.08), CELG: 108.62 (+0.37)

Gilead Prices $4 Billion of Senior Unsecured Notes
Business Wire - Wed Nov 12, 4:59PM CST
Gilead Sciences, Inc. (NASDAQ: GILD) today announced the pricing of senior unsecured notes in an aggregate principal amount of $4 billion, in an underwritten, registered public offering, consisting of three tranches:
GILD: 105.09 (-1.81)

Gilead Reports Promising Data on its HCV Drug Harvoni - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 4:00PM CST
Gilead Sciences, Inc. (GILD) announced pooled data from certain phase II and phase III studies evaluating Harvoni.
AGN: 197.49 (+0.98), JNJ: 109.37 (+0.62), GILD: 105.09 (-1.81), ABBV: 64.38 (+0.62)

Gilead Sciences Falls 1.03% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Wed Nov 12, 3:37PM CST
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $105.70 to a high of $107.81. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $106.33 on volume of 12.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GILD: 105.09 (-1.81)

Look for Shares of Gilead Sciences to Potentially Rebound after Yesterday's 1.03% Sell Off
Comtex SmarTrend(R) - Wed Nov 12, 3:37PM CST
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $105.70 to a high of $107.81. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $106.33 on volume of 12.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GILD: 105.08 (-1.82)

Gilead Sciences Gets Ambushed By The Patent Troll, AbbVie
Small Pharma Analyst - at Seeking Alpha - Wed Nov 12, 2:25PM CST

GILD: 105.08 (-1.82), ABBV: 64.38 (+0.62)

Sub-Optimal 39% Hep C Cure Rate Keeps Merck In Gilead's Rear View
Shock Exchange - at Seeking Alpha - Wed Nov 12, 2:13PM CST

GILD: 105.08 (-1.82), MRK: 59.89 (+0.58)

Should Investors Buy Twitter Following Its Analyst Day?
at The Street - Wed Nov 12, 2:08PM CST
The CNBC's 'Fast Money Halftime' trading panel says Twitter has a lot of potential but needs to find a way to grow its user base and engagement.
DHI: 24.39 (+0.38), FB: 74.60 (-0.12), WMT: 81.89 (+2.69), M: 60.96 (-0.61), BZH: 19.08 (+0.46), TLT: 118.62 (-0.01), DNKN: 48.94 (+0.85), SPY: 204.67 (+0.71), TJX: 63.71 (-0.02), EBAY: 54.46 (+0.40), QQQ: 103.22 (+0.76), GILD: 105.08 (-1.82), TGT: 67.61 (+0.89), DIA: 176.89 (+0.85), FL: 55.66 (-0.07), IWM: 117.99 (+0.09), TWTR: 42.71 (+0.17), TOL: 33.87 (+0.36), AAPL: 113.21 (+1.96)

Midday Glance: Biotechnology companies
AP - Wed Nov 12, 12:23PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are down at 1 p.m.:
GILD: 105.08 (-1.82), AMGN: 162.01 (+0.08), CELG: 108.62 (+0.37)

Searching The Stars For Quality Stocks
Brad Kenagy - at Seeking Alpha - Wed Nov 12, 10:43AM CST

PCAR: 66.98 (+0.08), GILD: 105.08 (-1.82), AMP: 130.42 (+0.14), CMCSA: 54.45 (+0.85)

Update: These 2 Combinations Will Further Strengthen Gilead's HCV Portfolio
IAEResearch - at Seeking Alpha - Wed Nov 12, 10:17AM CST

GILD: 105.08 (-1.82)

Early Glance: Biotechnology companies
AP - Wed Nov 12, 10:05AM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
GILD: 105.08 (-1.82), AMGN: 162.01 (+0.08), CELG: 108.62 (+0.37)

Biotech Stock Roundup: Gilead, AbbVie Score at Liver Meeting, Dendreon Files for Bankruptcy - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 12, 7:48AM CST
Companies like AbbVie (ABBV), Gilead (GILD) and Achillion (ACHN) had a strong presence at the annual Liver Meeting.
VRTX: 116.42 (-0.26), GILD: 105.08 (-1.82), ACHN: 14.61 (-0.24), DNDN: 0.15 (-0.01), AMGN: 162.01 (+0.08), ABBV: 64.38 (+0.62), REGN: 399.91 (-1.20)

Earnings Forecast Recap for Alibaba, Apple, Zynga, Gilead Sciences, Dendreon, and Juniper
PR Newswire - Wed Nov 12, 7:45AM CST
EarningForecast.com has issued six earnings forecast research reports with special focus on financial performance of the following stocks: Alibaba (NYSE:BABA), Apple (NASDAQ:AAPL), Zynga (NASDAQ:ZNGA), Gilead Sciences (NASDAQ:GILD), Dendreon (NASDAQ

NDN), and Juniper (NYSE:JNPR).
GILD: 105.08 (-1.82), DNDN: 0.15 (-0.01), ZNGA: 2.84 (+0.03), AAPL: 113.20 (+1.95), JNPR: 20.66 (-0.21), BABA: 118.45 (+0.25)

This Tiny Biotech Is Piggybacking on Gilead Sciences, Inc.'s Success
Todd Campbell, The Motley Fool - Motley Fool - Wed Nov 12, 7:43AM CST
Source: Gilead Sciences. Developing drugs that help established blockbusters work better is a major trend in biotechnology. It's a lower-stakes game because drug developers only need to show that their products can improve upon existing therapies,...
GILD: 105.08 (-1.82), ACHN: 14.61 (-0.24), MRK: 59.89 (+0.58)

Tracking The Parnassus Core Equity Fund
IVI Guy - at Seeking Alpha - Wed Nov 12, 6:45AM CST

WDFC: 77.99 (+0.18), SJR: 26.27 (+0.07), PRGO: 155.77 (+0.90), XYL: 37.42 (-0.13), CHRW: 72.88 (+0.02), MDLZ: 38.15 (+0.23), MKC: 73.46 (+0.23), MDU: 25.21 (-0.21), SYY: 38.88 (-0.06), PDCO: 45.73 (+0.60), PNR: 68.74 (+0.30), TRI: 38.20 (-0.04), UPS: 108.52 (-0.10), PEP: 98.62 (+1.46), AGN: 197.49 (+0.98), MSI: 64.36 (+0.66), NOV: 71.49 (-1.51), NWN: 47.04 (-0.05), EGN: 66.91 (-1.79), EBAY: 54.46 (+0.40), QCOM: 70.70 (+0.41), AMAT: 22.82 (+0.33), ACN: 84.55 (+0.43), AAPL: 113.20 (+1.95), MA: 84.27 (-0.08), SCHW: 28.81 (+0.03), STR: 23.84 (-0.10), SE: 38.26 (-0.70), GAS: 51.87 (-0.25), IRM: 38.09 (+0.04), WM: 49.38 (unch), CMP: 88.80 (+0.11), VRSK: 63.04 (-0.08), GILD: 105.08 (-1.82), EXPD: 43.87 (-0.04), TFX: 114.53 (+0.06), CVS: 90.03 (+0.74), PG: 89.76 (+0.28), PX: 126.61 (+0.38), NVS: 94.38 (+1.72)

Bristol-Myers Gives Updates on HCV Candidate Daclatasvir - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 5:41PM CST
Bristol-Myers Squibb Company (BMY) provided an update on its hepatitis C (HCV) candidate daclatasvir.
AGN: 197.49 (+0.98), GILD: 105.08 (-1.82), ABBV: 64.38 (+0.62), BMY: 58.03 (-0.58)

Gilead up on Harvoni results
at Investor's Business Daily - Tue Nov 11, 5:30PM CST
The drugmaker said that its new Harvoni drug achieved cure rates of 96%-97% in a study of patients who had cirrhosis and had failed to respond to prior treatments. Harvoni is Gilead's (GILD) hepatitis C pill that combines its blockbuster Sovaldi drug...
GILD: 105.08 (-1.82)

Gilead Sciences Inc. (GILD) Stock Research Links

GILD Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Illinois' Legal Tangle: Feds Under Fire?

What a tangled web Illinois lawmakers have woven this time. They've gone and cooked up a pair of laws with a real knack for attracting attention—specifically from the folks over at the National Police Association (NPA). These aren’t your run-of-the-mill rules; they feel more like a blueprint for putting federal officers through the legal wringer and turning courtroom...

VitalCore Pioneers Jail Behavioral Health Expansion

The Big Move in Correctional Healthcare VitalCore Health Strategies has made an impressive move with the opening of a 60-bed Behavioral Health Unit at Shawnee County Jail in Topeka, Kansas. The unit, part of a $21 million expansion completed on August 24, is set to change the landscape for inmates needing mental health and substance use treatment. This isn't just a slap...

Intellectia.AI Transforming Trading with AI Upgrades

Intellectia.AI Sparks New Trading Era Intellectia.AI, from the bustling streets of New York, is cutting through the noise with a flashy update to its AI-powered trading setup. They've thrown a heap of new toys into the ring, letting folks piggyback on high-grade stock moves in the blink of an eye. Gone are the days of fumbling with cumbersome data and execution. Breaking...

Stoke Space Raises $1B; XTEND AI Hits NYSE

A Billion-Dollar Boost for Stoke Space Ever catch wind of a company hauling in a cool billion and shrug it off? Me neither. Stoke Space Technologies just locked down $1 billion in Series E funding. This ain't some pocket change—the kind of dough you need when you're eyeing stars and plotting orbital voyages. They're gearing up for a 2027 mission with their Nova...

MADD, Uber Rally at Capital Invitational for Safe Choices

Driving Change at the Capital Invitational Let's talk about a powerhouse collaboration aiming to do more than just thrill basketball fans. We're looking at MADD Sports, Uber, and the Capital Invitational joining forces at The St. James in Springfield, Virginia, on December 10, 2026. This is not your average sporting event; it's a gathering with a bigger purpose. The...

Nashville Benefit Concert Supports Animal Rescue Mission

Country Tunes and Compassion Unite for Rescue Efforts There's something electric about a community banding together, especially when it's through the warmth of country music and the noble mission of animal rescue. Animal Rescue Corps (ARC), meeting ground for art and heart, is turning the Nashville Palace into a sanctuary not just for music, but for hope. They've got...

Muscle Car Fever Revs Up in New Global TV Series

Chasing the Dream on Wheels Amid the buzz of New York, there's a roar building up that's hard to ignore. It's a sound that echoes through time, capturing the imagination of petrol heads everywhere—those legendary American muscle cars are back in the limelight. I mean, who hasn't dreamt of launching down a highway in a '69 Ford Mustang? 'The Hunt for Rolling Treasure' is...

Hanover Unveils Skinny Veg® for GLP-1 Dieters

Seems like Hanover Foods is turning heads with their move into the ever-demanding health-conscious market. This family's stepping into the limelight with their new Skinny Veg® line, clearly targeting folks riding the GLP-1 wave. You see, it's not every day that a company that's been around the block since 1924 shakes things up like this. Simplicity is the Name of the...

Spot the Signs: Early Gum Disease Insights from Experts

Why Early Detection of Gum Disease Matters Let's dive right into the crux of things. Gum disease, that sneaky antagonist of oral health, starts unassumingly. You brush, you floss, but those gums might still bleed—ever noticed? Dr. Marian Burgard of Fairport Family Dental has a thing or two to say about this, enlightening us through an insightful piece by HelloNation....

Innventure Faces Major Lawsuit Amidst Market Turmoil

The Plot Thickens with Innventure's DarkNX Project Buckle up, fellow market sling-riders; the Innventure tale is a rocky one for the books. Imagine this: You’ve plunked down your hard-earned cash on Innventure Inc. (NASDAQ: INV), lured by their glowing pronouncements about a supposed golden egg project, the Accelsius DarkNX data-center deal. A big talk about...